// App-Quantinova.ai

OP0103 (2018) : Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis

Researchers

Presenter

  • H. Brunner

Principal Investigators

  • N. Ruperto

  • D. Lovell

  • I. Calvo-Penedes

  • G. Horneff

  • M.L. Gamir Gamir

  • M. Hufnagel

  • J. Hsu

  • M. Bao

  • W. Douglass

  • N.L. Mallalieu

  • C. Wells

  • C.M. Mela

  • F. De Benedetti

Medical Centers

  • Cincinnati Chldr-s Hosp Med C, Cincinnati, OH

  • Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, GENOA, Italy

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany

  • Hospital Ramon y Cajal, Madrid, Spain

  • Universitatsklinikum Freiburg, Freiburg, Germany

  • Roche Innovation Center, New York, NY

  • Roche Products Limited, Welwyn Garden City

  • Ospedale Pediatrico Bambino Gesu, Rome, Italy.

Locations

  • United States

  • Italy

  • Spain

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01904292

Sponsors

  • National Institutes of Health

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved